K to Z


    Medical Doctor, Consultant & Stanford Professor

    Shaping the future of healthcare in her pioneering Silicon Valley medical practice and work with leading companies, Dr. Molly Maloof is on the cutting edge of using personalized medicine, medical technology, health optimization, and scientific wellness
    to radically lengthen healthspan (the number of years that we can lead healthy, happy lives without disease or disability.) Dr. Molly’s bold vision includes making these practices more widely accessible as part of a U.S. healthcare system that is focused on improving health vs. waiting for chronic illness to develop. Unveiling the future of patient care with actionable insights on adopting the latest practices in personalized medicine, Dr. Molly challenges healthcare practitioners to re-think health and healthcare to reduce costs and improve patient outcomes.


    In her concierge practice, Dr. Molly provides health optimization and personalized medicine to high achieving entrepreneurs, investors and technology executives in San Francisco and the Silicon Valley. Her rigorous, data-driven approaches include comprehensive testing of clinical chemistry, metabolomics, microbiome, biometrics and genomic markers to increase performance and lengthen healthspan—the number of years that we can lead healthy, happy lives without disease or disability. Because dietary risks and fitness are responsible for the majority of lifestyle-related illness, she has become passionate about promoting innovative solutions for personalized nutrition.


    Since 2012, she has also worked as an advisor and/or strategy consultant to more than 25 companies in the digital health and biotechnology industries. Additionally, Dr. Molly has advised food and nutrition companies including Mars, Bayer, GlaxoSmithKline, Nature Made, Quaker, SomaWater, Red Bull and Thistle on health and human performance, with the goal of transforming our food system by improving corporate products. Dr. Molly has been invited to speak at numerous high profile conferences, including Wired Health, Women’s Entrepreneurship Day at the United Nations and Digital Life Design (DLD).


    Known for her unwavering mission to radically extend healthspan and maximize human performance, Dr. Molly is both a passionate evangelist, empowering advocate and visionary futurist. She is currently founding her first health technology company, and starting in April of 2019 she will be teaching a course on healthspan in the wellness department of the medical school at Stanford University.


    VP of Innovation and Research for Sanford Health

    DR. DAVID A. PEARCE, Ph.D., is VP Innovation and Research for Sanford Health. He completed his undergraduate Bachelor of Science degree with honors in biological sciences at Wolverhampton Polytechnic in 1986. He gained his Ph.D. in 1990 at the University of Bath, U.K., and did postdoctoral training at the University of Rochester, U.S., and Oxford University, U.K.


    Dr. Pearce heads the leading lab in Juvenile Batten disease research. He has been researching Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease) since 1997. His research has led to the first clinical trial for Juvenile Batten disease. He has published over 100 research papers on Batten disease. He also oversees a national registry for rare diseases known as the Coordination of Rare Diseases at Sanford (CoRDS). He has served on numerous U.S. National Institutes of Health (NIH) review committees, has organized rare disease workshops for the National Institute for Neurological Disorders and Stroke (NINDS) arm of the NIH and is currently a member of the executive committee for the International Rare Diseases Research Consortium (IRDiRC).


    In his role as Executive Vice President of Innovation and Research at Sanford, he is responsible for overseeing the development of research programs across Sanford’s nine-state footprint, including more than 450 researchers, eight research centers
    and more than 300 ongoing clinical trials. With this, he is also responsible for commercializing of select research strategies, as well as integrating Sanford Research operations into Sanford Health International Clinics. Driven by Dr. Pearce’s passion for developing patient-centered, impactful research programs, Sanford Research is uniquely positioned to provide translational research that can bring important discoveries from bench to bedside, improving the quality of care.


    CEO of Black Beret Life Sciences LLC

    DR. MARC PENN, MD, PhD, FACC is the CEO of Black Beret Life Sciences LLC (Houston, Texas), where he oversees the life science investments of the Bosarge Family Office and leads the executive teams of numerous companies, including Tissue Genesis LLC (Honolulu, Hawaii), Advanced Regen Medical Technologies LLC,(Newark, New Jersey), the novel sugar replacement, Sola®(Houston, Texas), and the Okyanos Center for Regenerative Medicine (Freeport, Bahamas). At Okyanos, he also serves as the director of research and strategy, working to advance stem cell therapeutics. He serves on the board of directors of Frantz Viral Therapeutics (Cleveland, Ohio) and Affigen (St. Louis, Missouri), and is an advisor to Diasome (Cleveland, Ohio).


    Dr. Penn is a practicing cardiologist and director of research at the Summa Health Heart and Vascular Institute (Akron, Ohio), as well as director of the institute’s Cardiovascular Medicine Fellowship. He is also a professor of medicine and integrative medical sciences at Northeast Ohio Medical University, where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics (Rootstown, Ohio). From 2000 to 2011, Dr. Penn was a cardiologist at the Cleveland Clinic, where he served as the director of the Coronary Intensive Care Unit, director of the Experimental Animal Laboratory, director of the Bakken Heart-Brain Institute and the founding director of the Center for Cardiovascular Cell Therapy. Dr. Penn is the principal investigator of the Athersys MultiStem®in AMI Phase I and II trials in Cleveland, Ohio. He has generated intellectual property in the fields of diagnostics, biologics, and devices that have been licensed by numerous companies. In 2006, he was named Innovator of the Year at the Cleveland Clinic. He was the co-founder and CMO of Cleveland HeartLab, which was acquired in 2017 by Quest Diagnostics.


    Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University, earning his Ph.D. in biomedical engineering in 1989 and his doctor of medicine degree in 1994. He performed his internal medicine training at University Hospitals of Cleveland and his cardiovascular medicine fellowship at the Cleveland Clinic. He is board–certified in internal medicine and cardiovascular medicine. From 2008 to 2010, Dr. Penn served as the senior medical director for Emerging Businesses at Cleveland Clinic.


    Dr. Penn’s research has led to several innovations in the field of cardiovascular medicine, including discoveries in diagnostics and drug delivery systems for the treatment of cardiovascular disease. He has developed strategies to optimize gene and stem cell therapy for regeneration of myocardial tissue, as well as neuromodulation of cardiac function. Dr. Penn is the author and co-author of hundreds of articles and abstracts on a wide range of scientific and medical topics. He is an active inventor and internationally recognized expert in translating basic science research to clinical populations.



    Director of Business Development for FutureHealth Alliance

    MORGAN PILE, CES, GBDS is an entrepreneur and the director of business development for FutureHealth Alliance. He is currently implementing regenerative medicine into employer’s health plans that will help many patients avoid surgery and help employers save millions. For over a decade, Morgan has been designing, implementing, and managing domestic and international networks, narrow networks, PBM management reviews, compliance reviews, population health management, regenerative medicine networks, and medical tourism as tools to help take control of rising health care costs. He graduated from Stetson University with a Bachelor in Finance as a merit scholar, and he has over fifteen years of experience consulting in human capital and benefits. Morgan is a certified enrollment specialist and a group benefits disability specialist. Focused on being a proactive agent for change, Morgan actively stops fraud, waste, and abuse in healthcare by managing fiduciary risk using innovative and cutting-edge solutions for clients. Morgan has experience working with self-funded employers, consultants, associations, municipalities, multinational corporations, international government entities, and healthcare providers. Morgan meets with self-funded employers to determine the strategy to address their fiduciary liability, which results in 10 to 30 percent savings by shifting the fiduciary liability away from the client. He has presented in several conferences all over the world, including the U.S., Korea, El Salvador, Argentina, Guatemala, Colombia, Croatia, Puerto Rico, Spain, and others. He is also a published author, with articles in The Self-Insurer, Self-Funded Magazine, and Medical Tourism Magazine.


    Chief Operating Officer of Caribbean Healthcare Partners, Ltd (CHP)

    Dr. Aboli Rane, PhD is the Senior Marketing Manager for Genetic Disease Research at Illumina, focusing on enabling and growing new markets in the Americas region. Over her last 7 years at Illumina, she led the commercial launch of Illumina’s flagship NovaSeq Sequencing Platform, as well as managed Illumina’s over half a billion-dollar high throughput consumables portfolio.

    Aboli obtained her B.S. in chemical engineering from Cornell University and her Ph.D.
    in bioengineering from the University of California, San Diego. Aboli serves on the Board of Directors for Key Conservation, an up-and-coming tech startup. She also chairs the committee for Life Sciences for Athena San Diego and previously sat on the Board of Directors of Athena.


    COO of a Single Family Office
    Founder of Salman Solutions

    Samira Salman is the COO of a Single Family Office and is the founder of Salman Solutions, an advisory firm that leads investors (family offices and high net worth individuals) in making direct investments into private companies. Additionally, Samira speaks globally on direct investments and fundraising and is a former professor of LSU Law School, where she taught a course she developed, entitled, Building Your Business and Your Brand.

    She is a former corporate tax attorney, was in-house counsel at Shell Oil Company, and was the vice chair of the American Bar Association Energy and Environmental Taxes Committee. She grew up in the Middle East and Europe, graduated from boarding school in Switzerland, and has a BS and JD from LSU and an LL.M. in Taxation from the University of Houston. She splits her time between New York and the Gulf Coast and travels globally for work.

  • Chief Operating OfficerCaribbean Healthcare Partners, Ltd (CHP)

    MARY MILLER SALLAH serves as Chief Operating Officer of Caribbean Healthcare Partners, Ltd (CHP), a private venture and healthcare real estate development firm. In this role, she is responsible for evaluating market trends and leading operations for the firm’s clinical facility investments, which includes buildings and property management, supply chain, clinical engineering, patient support services, partnerships, and marketing. Under her guidance, Operations is tasked with ensuring every facility and strategic relationship is designed and operating at optimal levels to address patients’ needs from the moment they step through our door in any CHP facility to the moment they leave to return home. Miller Sarah has been at the forefront of mapping out CHP’s international footprint and overseeing its growth strategy in the Caribbean and Central & South American markets.

    Before joining CHP, she built 15 years of experience managing healthcare facilities, international business development and international accreditation, and is considered an international expert in the field of medical travel, specifically in performance management, international standards, and the development, launching, and ongoing management of international and global patient services, medical tourism and medical travel programs.

    Miller Sallah’s professional experience covers over 30 international markets across North America, Central & South America, Africa, Asia and Europe. In 2016, as an inaugural team member, Miller Sallah launched the Global Healthcare Accreditation® (GHA) Program, the first independent international accreditation body focused on medical travel services. Prior to the launch of GHA, Miller Sallah was also the responsible executive for all education programs with the Medical Tourism Association© and worked at Duke University Medical Center. Miller Sallah obtained her Masters in Health Administration from the University of North Carolina at Chapel Hill Gillings School of Global Public Health and her Bachelors from the University of North Carolina Chapel Hill. She is a member of the American College of Healthcare Executives.


    Chief Medical Officer
    California Cryobank Life Sciences

    JAIME SHAMONKI, M.D. is the Chief Medical Officer of California Cryobank Life Sciences (established in 1997), a global industry-leading life sciences platform that includes the largest-in-class tissue banks offering reproductive services (California Cryobank Sperm Bank and Donor Egg Bank USA) and private newborn stem cell storage (Cord Blood Registry). Together, CCLS's subsidiaries support the corporate mission
    to grow and protect health families. Dr. Shamonki trained in anatomic and clinical pathology at New York Presbyterian Hospital – Weill Cornell Medical College, and
    has completed fellowships at Weill Cornell and the University of California, Los Angeles. Prior to joining CCLS, Dr. Shamonki developed expertise in women's health and clinical laboratory medicine, serving as the Director of Breast Pathology and Blood Bank Medical Director, at Saint John’s Health Center in Santa Monica, CA, and as an assistant professor at the John Wayne Cancer Institute. Dr. Shamonki is a recognized thought-leader, author and advocate for reproductive health and access to regenerative medicine.


    Chief Medical Officer
    EVP of Corporate Development J & B Medical

    STEPHEN SHAYA, MD graduated from Birmingham Brother Rice High School Summa Cum Laude. He was awarded a Merit Scholarship to attend Wayne State University. During his time at WSU, Dr. Shaya won many leadership awards, including the Outstanding Student Leader in 1991 and Howard Hughes Medical Institute Research Grant Awardee. He was selected to serve on the Wayne State University Board of Governors from 1991 to 1993. He attended Wayne State University Medical School and graduated in 1996. Dr. Shaya subsequently finished training in family practice at North Oakland Medical Center and a fellowship at Wayne State University for occupational and environmental health. Since 2004, Dr. Shaya has been the Chief Medical Officer and EVP of Corporate Development of J & B Medical, a global healthcare solutions company. J & B is a privately held global health care consortium based in Wixom, Michigan.

    Founded in 1996, J & B has sixteen different business enterprises and has customers in 48 states and 28 countries. This innovative company has brought many new ideas and solutions forward to the delivery care and continues to strive to improve patient access and quality. His role oversees all strategy, innovation and growth in the company. By leading the planning and development of their new enterprises, many describe him as an "intrapreneur," someone who behaves as an entrepreneur within a large organization.

    Dr. Shaya has received many recognitions, including becoming a Knight of Grace for the Knights of Malta, receiving the 2015 Global Distinguished Health Care Award from the Center of Economic and Leadership Development, and receiving a United States Congressional Commendation. Dr. Shaya received the Global Medical Innovation and Leadership Award on August 19, 2016, at the United Nations, along with a commendation from the New York State Senate. In 2017, Dr. Shaya was named the American Diabetes “Father of the Year.” Dr. Shaya spoke at the Vatican on April 28, 2018 on how leveraging technology could help extend care globally.


    • CEO & Co-Founder
      Fli Drone

    ROBERT SWEETING CEO & Co-Founder A Bahamian citizen, Nassau resident and graduate of the University of Central Florida Legal Studies program, Robert specializes in inter-island logistics. For years, he served as Director of Operations for multiple real estate developments on various family islands. He then went on to advise occupiers in the United States, such as Amazon, FedEx, and UPS, on how to streamline the supply chain through their real estate portfolios. Now, he is turning his focus to pioneering drone logistics in his home country.


    President of the non-profit Walsh Research Institute

    WILLIAM J. WALSH, PhD, FACN President of the non-profit Walsh Research Institute, is an internationally recognized expert in the field of nutritional medicine and a key scientist paving the way for nutrient-based psychiatry and nutritional medicine. Over the past 30 years, Dr. Walsh has developed biochemical treatments for patients diagnosed with behavioral disorders, attention deficit (hyperactivity) disorder, autism, clinical depression, anxiety, bipolar disorders, schizophrenia, and Alzheimer’s disease that are used by doctors throughout the world. His book, Nutrient Power: Heal Your Biochemistry and Heal Your Brain (Skyhorse Publishing, 2014, 2012), describes the evidence-based nutrient therapy system.

    Dr. Walsh’s noted accomplishments include: (a) groundbreaking studies reporting reduced violent behavior following nutrient therapy, (b) the 1999 discovery of undermethylation and copper/zinc imbalances in autism, (c) the 2000 finding of metallothionein protein depletion in autism, (d) the 2007 published study linking copper overload and post-partum depression, (e) the identification of five biochemical subtypes of clinical depression, (f) the 2011 development of the Walsh Theory of Schizophrenia, and (g) the direction of the Beethoven Research Project that revealed that the composer suffered from severe lead poisoning.

    ​In addition to Dr. Walsh’s ongoing research studies, he leads medical practitioner training programs in advanced, drug-free biochemical/nutrient therapies in Australia, Ireland, Norway, the United States, and other countries. Dr. Walsh is a frequently invited guest lecturer, having given more than 200 presentations at regional, national and international conferences and symposiums, including the American Psychiatric Association, the U.S. Senate, and the National Institutes of Mental Health. He has authored numerous peer-reviewed journal articles and scientific reports, as well as been granted five patents.

    After earning degrees from Notre Dame and the University of Michigan, Dr. Walsh received a PhD in chemical engineering from Iowa State University. While working at Argonne National Laboratory in the 1970s, Dr. Walsh organized a prison volunteer program that led to studies of prisoners and ex-offenders researching the causes of their violent behavior. The collaboration with renowned (late) Carl C. Pfeiffer, MD, PhD, a pioneer in the field of nutritional research therapy, led Dr. Walsh to the development of individualized nutrient protocols to normalize body chemistry and brain chemistry. Dr. Walsh went on to study more than 30,000 patients with mental disorders, acquiring an unparalleled database of more than 3 million chemical assays during his clinical and research work. He has assisted medical examiners, coroners, Scotland Yard, and the FBI in these forensics studies. He has designed nutritional programs for Olympic athletes, NBA players, major league baseball players, a heavyweight boxing champion, PGA and LPGA golfers, and others.